Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: SynapDx; Quidel; Med BioGene, Precision Therapeutics; CellHealth Institute

NEW YORK (GenomeWeb News) – SynapDx this week said that it has received a "significant investment" from The Kraft Group that will support ongoing clinical development of its molecular diagnostic test for autism spectrum disorder. Lexington, Mass.-based SynapDx didn't disclose the amount of the funding from Kraft.

In December the company announced that it had brought in $6 million through a Series A1 financing round. It also recently received a $2 million investment from Laboratory Corporation of America.

Quidel this week announced that it has received the CE Mark for its Molecular Direct HSV 1+2/VZV assay for the differentiation and detection of herpes simplex viruses 1 and 2 and varicella-zoster virus in active lesions. The PCR-based kit joins Quidel's other CE Marked molecular tests for influenza A+B, hMPV, RSV + hMPV, and C. difficile.

Med BioGene said that its marketing partner, Precision Therapeutics, has decided to rebrand the firm's LungExpress Dx test as GeneFx Lung. Precision currently markets several tests through its CLIA lab under the Fx name, including ChemoFx, BioSpeciFx, and GeneFx Colon. Precision expects to begin commercialization of GeneFx by mid-year, Med BioGene said in an announcement Wednesday.

Biotech firm CellHealth Institute launched today with a $2 million investment from Liberty Media Chairman John Malone. The company plans to collaborate with research universities and industry to offer personalized health programs in combination with scientific biomarker evaluations, medical grade supplements, and "advanced treatment through stem cell therapies," it said.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.